Optimal timing of apheresis for the efficient mobilization of peripheral blood progenitor cells recruited by high-dose granulocyte colony-stimulating factor in healthy donors.


Journal

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 24 12 2019
revised: 22 01 2020
accepted: 23 01 2020
pubmed: 14 2 2020
medline: 15 1 2021
entrez: 14 2 2020
Statut: ppublish

Résumé

Predictors of peripheral blood stem cell (PBSC) yield can potentially improve the comfort, safety, and efficacy of CD34+ cell collection from donors treated with recombinant human granulocyte colony-stimulating factor (G-CSF). We investigated 181 apheresis procedures on 109 healthy allogeneic donors to identify factors correlating with efficient PBSC collection. Apheresis started on Day 4 or 5 and continued up to Day 6 of G-CSF administration. CD34+ cell yields on Days 4 and 5 were comparable, and significantly higher than on Day 6. This suggests that starting apheresis on Day 4 rather than Day 5 may be preferable, to reduce G-CSF exposure and optimize yield, even if multi-day collection is required. More CD34+ cells were collected from male and cytomegalovirus (CMV)-seronegative donors than from female and CMV-seropositive donors, respectively. The yields of CD34+ cells were similarly high in both male and female donors aged 20-29 years; yields decreased in female donors in their thirties, and were comparably low in both male and female donors in their forties and thereafter. These findings should guide decision-making about when to begin apheresis, and encourage careful consideration of donor factors such as gender, age, and CMV serostatus when collecting PBSCs.

Identifiants

pubmed: 32051100
pii: S1473-0502(20)30020-3
doi: 10.1016/j.transci.2020.102737
pii:
doi:

Substances chimiques

Granulocyte Colony-Stimulating Factor 143011-72-7

Types de publication

Journal Article

Langues

eng

Pagination

102737

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Auteurs

Satoshi Kimura (S)

Department of Hematology, Fukushima Medical University, Fukushima, Japan.

Hiroshi Ohkawara (H)

Department of Hematology, Fukushima Medical University, Fukushima, Japan. Electronic address: ohkawara@fmu.ac.jp.

Keiji Minakawa (K)

Department of Blood Transfusion and Transplantation Immunology,Fukushima Medical University, Fukushima, Japan.

Masahiko Fukatsu (M)

Department of Hematology, Fukushima Medical University, Fukushima, Japan.

Hirotaka Mori (H)

Department of Hematology, Fukushima Medical University, Fukushima, Japan.

Hiroshi Takahashi (H)

Department of Hematology, Fukushima Medical University, Fukushima, Japan.

Kayo Harada-Shirado (K)

Department of Hematology, Fukushima Medical University, Fukushima, Japan.

Yoshihiro Ohara (Y)

Department ofPediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.

Nobuhisa Takahashi (N)

Department ofPediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.

Kazuhiro Mochizuki (K)

Department ofPediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.

Hideki Sano (H)

Department ofPediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.

Kenenth E Nollet (KE)

Department of Blood Transfusion and Transplantation Immunology,Fukushima Medical University, Fukushima, Japan.

Kazuei Ogawa (K)

Department of Hematology, Fukushima Medical University, Fukushima, Japan.

Hitoshi Ohto (H)

Department of Blood Transfusion and Transplantation Immunology,Fukushima Medical University, Fukushima, Japan.

Atsushi Kikuta (A)

Department ofPediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.

Kazuhiko Ikeda (K)

Department of Blood Transfusion and Transplantation Immunology,Fukushima Medical University, Fukushima, Japan.

Takayuki Ikezoe (T)

Department of Hematology, Fukushima Medical University, Fukushima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH